메뉴 건너뛰기




Volumn 23, Issue 12, 2009, Pages 817-825

Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; PLACEBO;

EID: 70749086889     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.28     Document Type: Article
Times cited : (16)

References (28)
  • 1
    • 0037079309 scopus 로고    scopus 로고
    • Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality: A meta-analysis of individual data for one million adults in 60 prospective studies
    • Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality: A meta-analysis of individual data for one million adults in 60 prospective studies. Lancet 2002; 14: 1903-1913.
    • (2002) Lancet , vol.14 , pp. 1903-1913
    • Lewington, S.1    Clarke, R.2    Qizilbash, N.3    Peto, R.4    Collins, R.5
  • 2
    • 0032513878 scopus 로고    scopus 로고
    • Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
    • Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.
    • (1998) Lancet , vol.351 , pp. 1755-1762
    • Hansson, L.1    Zanchetti, A.2    Carruthers, S.G.3    Dahlof, B.4    Elmfeldt, D.5    Julius, S.6
  • 3
    • 0038460302 scopus 로고    scopus 로고
    • The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high BP
    • Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high BP. JAMA 2003; 289: 2560-2572.
    • (2003) JAMA , vol.289 , pp. 2560-2572
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3    Cushman, W.C.4    Green, L.A.5    Izzo Jr, J.L.6
  • 4
    • 0037527647 scopus 로고    scopus 로고
    • European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension
    • Guidelines Committee
    • Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1054.
    • (2003) J Hypertens , vol.2003 , Issue.21 , pp. 1011-1054
  • 5
    • 0002548512 scopus 로고    scopus 로고
    • Angiotensin receptor antagonists
    • Oparil S, Weber MA eds, WB Saunders Co, Philadelphia
    • Ruddy MC, Kostis JB. Angiotensin receptor antagonists. In: Oparil S, Weber MA (eds). Hypertension. WB Saunders Co.: Philadelphia, 2000, pp 621-637.
    • (2000) Hypertension , pp. 621-637
    • Ruddy, M.C.1    Kostis, J.B.2
  • 6
    • 0034984319 scopus 로고    scopus 로고
    • Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: A multicenter, randomized, doubleblind, placebo-controlled parallel-group trial
    • McGill JB, Rilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: A multicenter, randomized, doubleblind, placebo-controlled parallel-group trial. Clin Ther 2001; 23: 833-850.
    • (2001) Clin Ther , vol.23 , pp. 833-850
    • McGill, J.B.1    Rilly, P.A.2
  • 7
    • 0037160968 scopus 로고    scopus 로고
    • Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomized trial against atenelol
    • Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomized trial against atenelol. Lancet 2002; 359: 995-1003.
    • (2002) Lancet , vol.359 , pp. 995-1003
    • Dahlof, B.1    Devereux, R.B.2    Kjeldsen, S.E.3    Julius, S.4    Beevers, G.5    de Faire, U.6
  • 8
    • 42049107348 scopus 로고    scopus 로고
    • Telmisartan, ramipril, or both in patients at high risk for vascular events
    • On Target Investigators
    • On Target Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
    • (2008) N Engl J Med , vol.358 , pp. 1547-1559
    • Yusuf, S.1    Teo, K.K.2    Pogue, J.3    Dyal, L.4    Copland, I.5    Schumacher, H.6
  • 9
    • 0035818884 scopus 로고    scopus 로고
    • A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
    • For the Valsartan Heart Failure Trial Investigators
    • Cohn JN, Tognoni G, For the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
    • (2001) N Engl J Med , vol.345 , pp. 1667-1675
    • Cohn, J.N.1    Tognoni, G.2
  • 10
    • 0035922441 scopus 로고    scopus 로고
    • Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    • Brenner BM, Cooper ME, deZeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
    • (2001) N Engl J Med , vol.345 , pp. 861-869
    • Brenner, B.M.1    Cooper, M.E.2    deZeeuw, D.3    Keane, W.F.4    Mitch, W.E.5    Parving, H.H.6
  • 11
    • 0035922447 scopus 로고    scopus 로고
    • Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    • Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 51-60.
    • (2001) N Engl J Med , vol.345 , pp. 51-60
    • Lewis, E.J.1    Hunsicker, L.G.2    Clarke, W.R.3    Berl, T.4    Pohl, M.A.5    Lewis, J.B.6
  • 12
    • 12344317534 scopus 로고    scopus 로고
    • Update on the management of hypertension: Recent clinical trials and the JNC 7
    • Moser M. Update on the management of hypertension: Recent clinical trials and the JNC 7. J Clin Hypertens 2004; 6: 4-13.
    • (2004) J Clin Hypertens , vol.6 , pp. 4-13
    • Moser, M.1
  • 13
    • 34547100641 scopus 로고    scopus 로고
    • Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily in the treatment of hypertension
    • White WB, Punzi H, Murwin D, Koval SE, Davidai G, Neutel JM. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily in the treatment of hypertension. J Clin Hypertens 2006; 8: 626-633.
    • (2006) J Clin Hypertens , vol.8 , pp. 626-633
    • White, W.B.1    Punzi, H.2    Murwin, D.3    Koval, S.E.4    Davidai, G.5    Neutel, J.M.6
  • 14
    • 38349042145 scopus 로고    scopus 로고
    • Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: A large, confirmatory trial
    • White WB, Murwin D, Chysant SG, Koval SE, Davidai G, Guthrie R. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: A large, confirmatory trial. Blood Press Monit 2008; 13: 21-27.
    • (2008) Blood Press Monit , vol.13 , pp. 21-27
    • White, W.B.1    Murwin, D.2    Chysant, S.G.3    Koval, S.E.4    Davidai, G.5    Guthrie, R.6
  • 15
    • 70749118993 scopus 로고    scopus 로고
    • Medical Dictionary for Regulatory Activities Terminology MedDRA, Version 9.1, MedDRA MSSO, Reston, VA, September 2006
    • Medical Dictionary for Regulatory Activities Terminology (MedDRA). Version 9.1, MedDRA MSSO, Reston, VA, September 2006.
  • 16
    • 1842562367 scopus 로고    scopus 로고
    • Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure
    • White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure. Am J Hypertens 2004; 17: 347-353.
    • (2004) Am J Hypertens , vol.17 , pp. 347-353
    • White, W.B.1    Lacourciere, Y.2    Davidai, G.3
  • 17
    • 0038204199 scopus 로고    scopus 로고
    • Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial
    • Giles TD, Bakris GL, Smith DHG, Davidai G, Weber MA. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens 2003; 16: 460-466.
    • (2003) Am J Hypertens , vol.16 , pp. 460-466
    • Giles, T.D.1    Bakris, G.L.2    Smith, D.H.G.3    Davidai, G.4    Weber, M.A.5
  • 19
    • 0032436072 scopus 로고    scopus 로고
    • Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy
    • Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861-866.
    • (1998) J Hum Hypertens , vol.12 , pp. 861-866
    • Benz, J.R.1    Black, H.R.2    Graff, A.3    Reed, A.4    Fitzsimmons, S.5    Shi, Y.6
  • 20
    • 12744263227 scopus 로고    scopus 로고
    • Fixed-dose combinations in the management of hypertension: Defining the place of angiotensin receptor antagonists and hydrochlorothiazide
    • Kjeldsen SE, Os I, Hoieggen A, Beckey K, Gleim GW, Oparil S. Fixed-dose combinations in the management of hypertension: Defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005; 5: 17-22.
    • (2005) Am J Cardiovasc Drugs , vol.5 , pp. 17-22
    • Kjeldsen, S.E.1    Os, I.2    Hoieggen, A.3    Beckey, K.4    Gleim, G.W.5    Oparil, S.6
  • 21
    • 0036257168 scopus 로고    scopus 로고
    • Candesartan cilexetil plus hydrochlorothiazide combination: A review of its use in hypertension
    • Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: A review of its use in hypertension. Drugs 2002; 62: 787-816.
    • (2002) Drugs , vol.62 , pp. 787-816
    • Melian, E.B.1    Jarvis, B.2
  • 22
    • 0041589771 scopus 로고    scopus 로고
    • Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension - a randomized ABPM study
    • Neutel JM, Kolloch RE, Plouin PF, Meinicke TW, Schumacher H. Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension - a randomized ABPM study. J Hum Hypertens 2003; 17: 569-575.
    • (2003) J Hum Hypertens , vol.17 , pp. 569-575
    • Neutel, J.M.1    Kolloch, R.E.2    Plouin, P.F.3    Meinicke, T.W.4    Schumacher, H.5
  • 23
    • 1442299290 scopus 로고    scopus 로고
    • Evaluation of the antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide
    • Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of the antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17: 252-259.
    • (2004) Am J Hypertens , vol.17 , pp. 252-259
    • Chrysant, S.G.1    Weber, M.A.2    Wang, A.C.3    Hinman, D.J.4
  • 24
    • 0034932549 scopus 로고    scopus 로고
    • A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II
    • Vidt DG, White WB, Ridley E, Rahman M, Harris S, Vendetti J et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 2001; 15: 471-480.
    • (2001) J Hum Hypertens , vol.15 , pp. 471-480
    • Vidt, D.G.1    White, W.B.2    Ridley, E.3    Rahman, M.4    Harris, S.5    Vendetti, J.6
  • 25
    • 21344471995 scopus 로고    scopus 로고
    • Efficacy and safety of valsartan 160 mg/hydrochlorothiazide 25 mg combination in patients with hypertension not adequately controlled by valsartan 160 mg/ hydrochlorothiazide 12.5 mg
    • Trenkwalder P, Ulmer HJ, Weidinger G, Handrock R. Efficacy and safety of valsartan 160 mg/hydrochlorothiazide 25 mg combination in patients with hypertension not adequately controlled by valsartan 160 mg/ hydrochlorothiazide 12.5 mg. Clin Drug Invest 2004; 24: 593-602.
    • (2004) Clin Drug Invest , vol.24 , pp. 593-602
    • Trenkwalder, P.1    Ulmer, H.J.2    Weidinger, G.3    Handrock, R.4
  • 26
    • 0028927046 scopus 로고
    • Implications of small reductions in diastolic blood pressure for primary prevention
    • Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155: 701-709.
    • (1995) Arch Intern Med , vol.155 , pp. 701-709
    • Cook, N.R.1    Cohen, J.2    Hebert, P.R.3    Taylor, J.O.4    Hennekens, C.H.5
  • 27
    • 0344373794 scopus 로고    scopus 로고
    • The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
    • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
    • (2002) JAMA , vol.288 , pp. 2981-2997
  • 28
    • 2942635317 scopus 로고    scopus 로고
    • VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
    • Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.
    • (2004) Lancet , vol.363 , pp. 2022-2031
    • Julius, S.1    Kjeldsen, S.E.2    Weber, M.3    Brunner, H.R.4    Ekman, S.5    Hansson, L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.